Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.

Date publication

octobre 2021

Journal

Breast cancer research and treatment

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EYMARD Jean-Christophe , Pr PETIT Thierry

Tous les auteurs :
Corbaux P, Lardy-Cleaud A, Alexandre M, Fontanilles M, Lévy C, Viansone AA, Mailliez A, Debled M, Goncalves A, Le Du F, Lerebours F, Ferrero JM, Eymard JC, Mouret-Reynier MA, Petit T, Frenel JS, Dalenc F, Courtinard C, Chaix M, Bachelot T

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34687411

Résumé

A major question when treating HR+/HER2- metastatic breast cancer (MBC) is whether early introduction of chemotherapy (CT) increases endocrine resistance. We aimed to describe progression-free survival (PFS) under first endocrine therapy (ET) depending on whether given before or after CT in a large nationwide cohort, in the pre-CDK era.

Mots clés

Advanced breast cancer, Chemotherapy, Endocrine therapy, HR+/HER2−, Progression-free survival, Real-word data

Référence

Breast Cancer Res Treat. 2021 Oct 23;: